Jason D. Wright, MD, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.
Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.
Olaparib was recently approved for ovarian cancer.Read more > >
Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer
July 22nd 2024An analysis from the innovaTV 301 showed that tisotumab vedotin in the second- and third-line bettered overall survival vs investigator’s choice of chemotherapy in patients with cervical cancer.
Read More